Relmada Therapeutics (RLMD) Tops Q3 EPS by 18c

Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($0.73), $0.18 better than the analyst estimate of ($0.91).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Summit Hotel Properties refinances $650M credit facility through 2031
• Relmada Therapeutics added to Russell 2000 and Russell 3000 indexes